| Host: |
Mouse |
| Applications: |
IHC-P |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Mouse monoclonal antibody anti-P63 is suitable for use in Immunohistochemistry research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
TP63/11 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG2a |
| Formulation: |
Bioreactor Concentrate with 0.05% Azide |
| Purification: |
Concentrate |
| Dilution Range: |
IHC-P 1:400-1:800 |
| Storage Instruction: |
Store at 2-8°C upon receipt. |
| Immunogen: |
Recombinant human p63 protein |
| Background | p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratin s and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC) , with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC) , is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts. Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections. Note: Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended. Control tissue Breast, Prostate, Prostate carcinoma or lung or bladder squamous cell carcinoma |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
